CCM
FLXN

Consonance Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Consonance Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-217,392
Closed -$5.62M – 31
2018
Q2 		$5.62M Buy
217,392
+10,000
+5% +$259K 0.36% 29
2018
Q1 		$4.65M Buy
+207,392
New +$5.06M 0.42% 26

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Consonance Capital Management's FLXN Position: Q3 2018 in Review

Consonance Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2018, closing a stake of 217,392 shares — an estimated $5.62M sold.

Consonance Capital Management first reported a position in FLXN in Q1 2018 and held it in 2 quarters. The position peaked at $5.62M in Q2 2018. 129 funds tracked by Wall St. Rank hold FLXN as of Q3 2018.

  • Consonance Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Consonance Capital Management sold 217,392 Flexion Therapeutics, Inc. shares in Q3 2018, an estimated $5.62M.
  • Consonance Capital Management first reported a position in Flexion Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
  • Consonance Capital Management's Flexion Therapeutics, Inc. position peaked at $5.62M in Q2 2018.
  • 129 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2018.

Based on Consonance Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.